Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Stopped The sponsor decided to terminate the study due to financial issues following an FDA request for a partial clinical hold.

Conditions

• Relapsed Multiple Myeloma
• Relapsed-Refractory Multiple Myeloma

Interventions

• DRUG: Melflufen
• DRUG: Dexamethasone
• DRUG: Daratumumab

Sponsor

Oncopeptides AB